US FDA Approved Lung Cancer Drug by Mirati Therapeutics

The US Food and Drug Administration (FDA) has approved KRAZATI, a targeted treatment for adult patients with KRAS metastatic non-small cell lung cancer (NSCLC), developed by Mirati Therapeutics Inc. Based on the objective response rate (ORR) and duration of response (DOR), the treatment receives expedited approval. The description and verification of a clinical benefit in […]

Continue Reading